Oxford Biomedica is a gene and cell therapy group focused on developing treatments for serious diseases based around its FDA approved lentiviral vector delivery platform. The Company leverages this platform to develop in vivo and ex vivo products in-house and with global Pharmaceutical and Biotech partners and has created it's own portfolio of gene and cell therapy product candidates.

Total Voting Rights

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Oxford Biomedica PLC (OXB LN)

Total Voting Rights

Holding(s) in Company

Total Voting Rights

OXB honoured at 2025 CDMO Leadership Awards Europe

OXB to participate in investor conferences

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)